Ionis Pharmaceuticals (IONS) Announces Quarterly Earnings Results

Ionis Pharmaceuticals (NASDAQ:IONS) released its quarterly earnings data on Thursday. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.19, MarketWatch Earnings reports. Ionis Pharmaceuticals had a return on equity of 49.13% and a net margin of 47.74%. The business had revenue of $297.00 million during the quarter, compared to analysts’ expectations of $285.43 million. During the same quarter last year, the business posted ($0.01) EPS. The business’s revenue was up 106.3% on a year-over-year basis.

NASDAQ IONS traded up $1.92 on Friday, hitting $69.28. The company’s stock had a trading volume of 1,347,381 shares, compared to its average volume of 1,548,228. Ionis Pharmaceuticals has a 52-week low of $40.91 and a 52-week high of $86.58. The company has a debt-to-equity ratio of 0.53, a quick ratio of 7.85 and a current ratio of 7.88. The stock has a market cap of $9.68 billion, a P/E ratio of 23.41 and a beta of 2.31.

Several research firms have weighed in on IONS. Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, April 13th. ValuEngine cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Cantor Fitzgerald reiterated a “hold” rating on shares of Ionis Pharmaceuticals in a report on Thursday, April 18th. Finally, Piper Jaffray Companies set a $75.00 price objective on Ionis Pharmaceuticals and gave the stock a “neutral” rating in a report on Friday, March 22nd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $66.44.

In other news, Chairman Stanley T. Crooke sold 46,904 shares of the firm’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $60.09, for a total value of $2,818,461.36. Following the completion of the transaction, the chairman now owns 109,634 shares in the company, valued at approximately $6,587,907.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Stanley T. Crooke sold 77,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $60.77, for a total value of $4,679,290.00. Following the completion of the transaction, the chairman now owns 109,634 shares of the company’s stock, valued at approximately $6,662,458.18. The disclosure for this sale can be found here. In the last quarter, insiders sold 400,592 shares of company stock valued at $29,395,319. Company insiders own 2.44% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Ionis Pharmaceuticals by 12.1% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,485 shares of the company’s stock valued at $121,000 after purchasing an additional 160 shares during the period. Carroll Financial Associates Inc. lifted its stake in shares of Ionis Pharmaceuticals by 27.4% in the 1st quarter. Carroll Financial Associates Inc. now owns 762 shares of the company’s stock valued at $61,000 after purchasing an additional 164 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Ionis Pharmaceuticals by 9.0% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,268 shares of the company’s stock valued at $184,000 after buying an additional 188 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in Ionis Pharmaceuticals by 29.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock valued at $48,000 after buying an additional 200 shares during the last quarter. Finally, Keybank National Association OH raised its stake in Ionis Pharmaceuticals by 1.2% during the fourth quarter. Keybank National Association OH now owns 21,606 shares of the company’s stock valued at $1,168,000 after buying an additional 250 shares during the last quarter. Institutional investors own 84.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2019/05/11/ionis-pharmaceuticals-ions-announces-quarterly-earnings-results.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Read More: Do equity income investments outperform growth and income investments?

Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.